Semaglutide vs. Tirzepatide: The Only Comparison That Doesn't End With "It Depends on Your Body"

Both mimic GLP-1, a gut hormone that tells your brain you're full, slows gastric emptying, and helps regulate blood sugar. Both are weekly subcutaneous injections. Both are titrated by your provider. Both are available as compounded formulations through IVUSE+. That's the shared playbook.

Here's the fork.

One button vs. two

Semaglutide targets one receptor: GLP-1. Single agonist. Longer track record, more published data, on the market since 2017.

Tirzepatide targets two receptors: GLP-1 and GIP. Dual agonist. In head-to-head clinical trials, it showed greater average weight reduction and greater A1C improvement at comparable timepoints.

Two buttons where semaglutide pushes one. That doesn't make tirzepatide universally "better." It makes it a different tool with a different receptor profile. The person on Reddit who lost more on one than the other isn't wrong about their experience. They're just not your endocrinologist.

What your provider is actually weighing

The provider reviewing your IVUSE+ assessment isn't scrolling the same TikTok you are. They're weighing your starting metabolic markers, your goals once you strip the wellness language off them, your GI tolerance window, and your history. If you've been on semaglutide and plateaued, tirzepatide's dual mechanism may restart movement. If tirzepatide's side effects are running your week, semaglutide may be the tolerable path. Your provider has context that a comparison chart doesn't.

Both compounded formulations are prepared by licensed U.S. compounding pharmacies for the individual patient, based on the provider's prescription. They're the same active molecules as the branded products you've seen in the headlines, compounded and dosed for you.

Forget the scale for a second

The early GLP-1 conversation was a weight-loss conversation. Pounds dropped. Scale screenshots. Caption: "month three." That framing was never the whole picture.

Both semaglutide and tirzepatide reduce body fat. But any caloric deficit, including one driven by appetite suppression, can also reduce lean muscle mass if you're not actively working to preserve it. That's not a flaw of the medication. That's a reality of weight change that applies to every approach, including the 1,200-calorie diet your coworker swore by in 2019 that she now pretends she never did.

You can drop twenty pounds and look worse if fifteen of them were muscle. You can drop twelve and look like a different person if ten were visceral fat and you built lean tissue alongside the loss. The question was never how much. It's what kind.

That's why the current clinical conversation has shifted to recomposition: pairing GLP-1 therapy with resistance training and adequate protein to shift the ratio toward fat loss while preserving muscle. The goal is a body that's leaner, stronger, and more capable. Not a smaller number on a device that can't tell the difference between muscle, water, and the burrito you had last night.

BPC-157, a recovery peptide available through IVUSE+, is studied for gut comfort and connective tissue support. Some patients use it alongside their GLP-1 protocol, especially during the early titration window or when training intensity outpaces recovery. Your provider can discuss whether it fits.

What these won't do

They won't build muscle. They won't fix your sleep. They won't undo the cortisol from a job you hate. They'll quiet the food noise that made eating less feel like a daily referendum on your willpower. That's the window. What you do inside it is yours.

They also won't work identically for everyone. Some patients respond strongly to semaglutide and moderately to tirzepatide, or the reverse. Some need dose adjustments three or four times. That's not failure. That's a provider paying attention.

So which one

Semaglutide: single agonist, deeper data, longer track record. Tirzepatide: dual agonist, stronger average numbers in trials, second receptor in play. Your provider picks based on your profile, not on which molecule had a better month on social media.

If you're not sure which is right, good. That's what the assessment is for.

Compounded medications are not FDA-approved. They are prepared by licensed U.S. compounding pharmacies for an individual patient based on a provider's prescription. These statements have not been evaluated by the FDA. This content is educational and does not constitute medical advice. Your provider determines what's appropriate for you.